Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


pMXs-hu-N-Myc Citations (3)

Originally described in: Promotion of direct reprogramming by transformation-deficient Myc.
Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S Proc Natl Acad Sci U S A. 2010 Jul 26. ():.
PubMed Journal

Articles Citing pMXs-hu-N-Myc

Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma. Dalton KM, Krytska K, Lochmann TL, Sano R, Casey C, D'Aulerio A, Khan QA, Crowther GS, Coon C, Cai J, Jacob S, Kurupi R, Hu B, Dozmorov M, Greninger P, Souers AJ, Benes CH, Mosse YP, Faber AC. Mol Cancer Ther. 2021 Aug;20(8):1400-1411. doi: 10.1158/1535-7163.MCT-20-0710. Epub 2021 Jun 4. PubMed
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma. Floros KV, Chawla AT, Johnson-Berro MO, Khatri R, Stamatouli AM, Boikos SA, Dozmorov MG, Cowart LA, Faber AC. Cell Stress. 2022 Jan 17;6(2):21-29. doi: 10.15698/cst2022.02.264. eCollection 2022 Feb. PubMed
Targeting TRIM24 promotes neuroblastoma differentiation and decreases tumorigenicity via LSD1/CoREST complex. Shi Q, Yu B, Zhang Y, Yang Y, Xu C, Zhang M, Chen G, Luo F, Sun B, Yang R, Li Y, Feng H. Cell Oncol (Dordr). 2023 Jul 19. doi: 10.1007/s13402-023-00843-4. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.